KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Receivables (2017 - 2025)

Twist Bioscience (TWST) has disclosed Change in Receivables for 7 consecutive years, with $1.8 million as the latest value for Q3 2023.

  • On a quarterly basis, Change in Receivables rose 373.72% to $1.8 million in Q3 2023 year-over-year; TTM through Sep 2023 was $4.3 million, a 55.1% decrease, with the full-year FY2024 number at -$8.4 million, down 295.46% from a year prior.
  • Change in Receivables was $1.8 million for Q3 2023 at Twist Bioscience, up from -$5.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $13.0 million in Q3 2020 to a low of -$5.5 million in Q2 2023.
  • A 5-year average of $1.9 million and a median of $1.8 million in 2020 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 2158.06% in 2020, then crashed 328.28% in 2022.
  • Twist Bioscience's Change in Receivables stood at $950000.0 in 2019, then tumbled by 193.05% to -$884000.0 in 2020, then soared by 329.86% to $2.0 million in 2021, then soared by 101.67% to $4.1 million in 2022, then crashed by 55.78% to $1.8 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Change in Receivables are $1.8 million (Q3 2023), -$5.5 million (Q2 2023), and $4.0 million (Q1 2023).